-transparent.png){kind=logo}
Recombinant human interferon-alpha has been used in the treatment of several cancers, but there have been several reports that it may exacerbate psoriasis or trigger off its onset. We report four patients, three of whom first developed psoriasis and one who had an aggravation of the condition during treatment with interferon-alpha. Three of the patients had the carcinoid syndrome and one a renal carcinoma, and all were treated with interferon-alpha 2b or 2a (IFN-alpha 2b, 2a) with doses ranging from 1.5 x 10(6) U daily to 18 x 10(6) U three times weekly. In two of the patients there appeared to be a correlation between the severity of the psoriasis and the dosage of interferon.
J Funk, and
T Langeland, and
E Schrumpf, and
L E Hanssen
February 1996,
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
J Funk, and
T Langeland, and
E Schrumpf, and
L E Hanssen
January 1996,
Annales de medecine interne,
J Funk, and
T Langeland, and
E Schrumpf, and
L E Hanssen
March 2018,
Pediatric dermatology,
J Funk, and
T Langeland, and
E Schrumpf, and
L E Hanssen
March 2016,
Cutaneous and ocular toxicology,
J Funk, and
T Langeland, and
E Schrumpf, and
L E Hanssen
October 1993,
Acta dermato-venereologica,
J Funk, and
T Langeland, and
E Schrumpf, and
L E Hanssen
June 1986,
Lancet (London, England),
J Funk, and
T Langeland, and
E Schrumpf, and
L E Hanssen
December 1994,
Medicina clinica,
J Funk, and
T Langeland, and
E Schrumpf, and
L E Hanssen
January 2005,
European journal of dermatology : EJD,
J Funk, and
T Langeland, and
E Schrumpf, and
L E Hanssen
January 2002,
Psychosomatics,
J Funk, and
T Langeland, and
E Schrumpf, and
L E Hanssen
January 1987,
Dermatologica,
